Les Entreprises du médicament en France (Leem), an association of French pharmaceutical companies, unveiled its manifesto on Friday (May 17) ahead of June's EU elections, with the focus on investing in research and development (R&D) to avoid falling behind the United States.
French delegate minister of Industry Roland Lescure visited the production site of Italian pharmaceutical group Chiesi in the Loir-et-Cher département on Tuesday (May 14), after the company announced an investment of €10 million.
France is the European country with the highest tax burden for pharmaceutical companies, according to a study published on Thursday (May 2) by Entreprises du Médicament en France (Leem), an association of French pharmaceutical companies.
Marie Toussaint, the lead of the French Greens' campaign for the June European elections, presented a plan for a "European pharmaceutical sovereignty" at a press conference on Friday (19 April), after media reported that a French pharma company could be acquired by Indian buyers.
Against the backdrop of the upcoming European elections, could the EU do more to positively affect healthcare outcomes across the EU 27 in the next legislative cycle? Astra Zeneca’s Stefan Woxström believes now is the time to seize the momentum.
The EU’s new pharma legislation package could be the medicine Europe needs to boost biotech innovation, but industry says it doesn’t go far enough.
The European Commission will call for "cooperation between different stakeholders to bring about positive change" in the pharmaceutical sector, according to a leaked communication accompanying the revision of the EU's drug framework.
The further postponement of the publication of the EU pharma legislation has caused tensions to rise among EU lawmakers and health stakeholders, who have demanded the Commission expedite it to start the legislative process on time.
The unveiling of the much-awaited reform of the EU's regulatory framework for pharmaceuticals has been pushed back to a later date for the third time in just a few months, EURACTIV has learnt.
With only a few weeks before unveiling the EU's revamped framework for pharmaceuticals, Health Commissioner Stella Kyriakides described the main drivers of the much-awaited reform, stressing the importance of finding the balance between patients' and industry's interests.
As the EU seeks to ensure that patients across all its countries have access to modern, affordable medicines in sufficient quantities, experts warn that the current system is financially unsustainable and call for a change.
The vibrant biotech sector is ready to showcase what European businesses can do when it comes to human health while waiting for more initiatives at the policy level.
Both the European Parliament and the World Health Organisation (WHO) have reiterated the need to update the regulations on medicines for children and orphan drugs, in order to better address unmet needs of children and adolescents in cancer care.
The market will not regulate itself when it comes to finding solutions to rare diseases, said Sandra Gallina, director at the European Commission’s DG SANTE, adding there is pressure to kickstart innovation on orphan drugs.
The public-private partnership ‘Innovative Health Initiative’ (IHI), built on the 14 years of experience from the previous ‘Innovative Medicines Initiative’(IMI), expands its scope, focusing less directly on pharmaceuticals and more broadly on health care.
MEPs adopted a draft report on Tuesday (12 October) aimed at strengthening the EU's pharmaceutical strategy to ensure every patient has reliable and timely access to medicines, as shortages have been increasing since 2000. EURACTIV France reports.
The revision of the legislative framework of pharmaceuticals and of medicines for children and rare diseases will drop the curtain on next year's Commission agenda as they are expected to be adopted in December 2022.
EU policymakers are being urged to consider the full range of new incentive systems and pilot innovative approaches to tackle antimicrobial resistance (AMR), including Netflix-style subscription services and pull incentives.
The European Parliament will put pressure on the Commission and the member states to provide the necessary regulatory framework for nanomedicines in order to better make use of their potential for patients, EU lawmaker Pietro Fiocchi told EURACTIV in an interview.
The European Commission will examine specific incentives and a new pricing system to develop innovative antibiotics in its pharmaceutical strategy, in a bid to take a more ambitious stance against the rising threat of anti-microbial resistance (AMR).
Affordability, availability and sustainability are the main focus points of the EU’s new pharmaceutical strategy, due to be published on Wednesday (25 November).
There is an urgent need for specific recommendations over lung-cancer screening at the highest political levels in order to detect early and tackle lung cancer, the “biggest killer cancer”, stakeholders have said.
Europe needs to give EU Orphan Drugs regulation more time to show its effectiveness before reviewing the incentives it provides and putting pharma innovation to the test, economist Adam Hutchings told EURACTIV in an interview.
In the absence of the EU orphan drugs regulation, which focuses on rare diseases, approximately two million patients would not get access to therapies, a new industry-funded report has found.
